Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jeffrey M. Clarke"'
Autor:
John V. Heymach, Robin Cornelissen, Jonathan W. Goldman, Francois Lebel, Nishan Tchekmedyian, Gajanan Bhat, Szu-Yun Leu, Xiuning Le, Mark A. Socinski, Jeffrey M. Clarke, Marina Chiara Garassino
Publikováno v:
Journal of Clinical Oncology, 40(7), 710-718. American Society of Clinical Oncology
PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene ( ERBB2 or HER2) exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in pre
Autor:
Sharon Leu, Robin Cornelissen, Mark A. Socinski, Jeffrey M. Clarke, Francois Lebel, Xiuning Le, Julian R. Molina, Marina Chiara Garassino, Christina S Baik, Nishan Tchekmedyian, Lyndah Dreiling
Publikováno v:
Journal of Clinical Oncology. 39:9093-9093
9093 Background: Treatment addressing non-small cell lung cancer (NSCLC) harboring EGFR or HER2 exon 20 insertion mutations remains an unmet need. These tumors are associated with a high incidence of CNS metastases and unfavorable survival rates. Poz
Autor:
Jonathan W. Goldman, Nishan Tchekmedyian, David Chu, Gajanan Bhat, Xiuning Le, Zofia Piotrowska, Mark A. Socinski, Jeffrey M. Clarke, Francois Lebel
Publikováno v:
Journal of Clinical Oncology. 38:9514-9514
9514 Background: Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations is an unmet medical need. Poziotinib is a potent tyrosine kinase inhibitor (TKI) of EGFR and HER2 exon 20 insertion mutants. We evaluated the efficacy and sa
Autor:
Jeffrey M. Clarke, Jeffrey Crawford, Scott J. Antonia, Xiaofei Wang, Afreen Shariff, Tom Stinchcombe, Jennifer Garst, Sundhar Ramalingam, Neal Ready, Marvaretta Stevenson, Lin Gu
Publikováno v:
Journal of Clinical Oncology. 38:e21683-e21683
e21683 Background: Combination chemo-immunotherapy is a well-established frontline therapeutic option for treatment naïve NSCLC. Dual immune checkpoint blockade (ICB) with nivolumab (nivo) and ipilimumab (ipi) has demonstrated improved clinical outc
Autor:
Jeffrey M. Clarke, Michael R. Harrison, Michelle F. Green, Andrew J. Armstrong, Daniel J. George, John H. Strickler, Eric Powers, Chester Kao, Tian Zhang, Michael B. Datto
Publikováno v:
Journal of Clinical Oncology. 38:80-80
80 Background: TMB is a promising predictive biomarker for ICB, but recent studies have shown that TMB varies substantially between tumor types. We examined the association between TMB and clinical response to ICB in metastatic urothelial carcinoma (
Autor:
Victoria Jennifer Stefaniak, Zhanglin Lin Cui, Andrew D. Norden, Martin Gutierrez, Jeffrey M. Clarke, Eric Hansen, Marta Batus, Katherine B. Winfree, Cliff Molife, Andrew J. Belli, Chelsea Manion, Philip Bonomi, Viraj Narayanan
Publikováno v:
Journal of Clinical Oncology. 37:e20706-e20706
e20706 Background: Despite advances in therapy, recent observational data shows that aNSCLC pts with RDP continue to have a poor prognosis. This retrospective, observational study characterizes the demographic, molecular, & treatment profile of pts w
Autor:
Rebecca Nagy, Kimberly C. Banks, Richard B. Lanman, Victoria M. Raymond, Bianca E. Amador, Sai-Hong Ignatius Ou, Trever G. Bivona, Young Kwang Chae, Viola W. Zhu, Patrick Kwok Shing Ng, Jeffrey Crawford, Jeffrey M. Clarke, Marcelo V. Negrao, John V. Heymach, Emily Roarty, Caroline E. McCoach, David R. Gandara
Publikováno v:
Journal of Clinical Oncology. 37:3102-3102
3102 Background: BRAF alterations (alts) account for ~4% of non-small cell lung cancers (NSCLC) with 50% being non-V600 alts. Because these alts are functionally heterogeneous and have a poorly characterized genomic landscape, determining appropriate
Autor:
Lucy Mitchell, Jeffrey M. Clarke, Marta Batus, Philip Bonomi, Katherine B. Winfree, Cliff Molife, Victoria Jennifer Stefaniak, Zhanglin Lin Cui
Publikováno v:
Journal of Clinical Oncology. 37:e20723-e20723
e20723 Background: Clinical trials have shown that aNSCLC patients (pts) with AD, including those with rapid disease progression (RDP) on initial therapy (time to progression ≤ 12 weeks), have poor prognosis. This retrospective study evaluates the
Autor:
David Lenis, Shrujal S. Baxi, Jeffrey M. Clarke, Philip Bonomi, Marta Batus, Victoria Jennifer Stefaniak, Raina Mathur, Cliff Molife, Zhanglin Lin Cui, Katherine B. Winfree
Publikováno v:
Journal of Clinical Oncology. 37:e20725-e20725
e20725 Background: In REVEL, adding ramucirumab to docetaxel improved response rates among Pt-treated aNSCLC pts. This observational study evaluated rwTR in aNSCLC pts treated with R+D after Pt & ICI or other (non-ICI) therapies. Methods: Adult aNSCL
Autor:
Ben Breton, Daniel C. Cho, Jeffrey M. Clarke, Celine Robert-Tissot, Manish R. Patel, Martin Gutierrez, Jing Sun, Tal Zaks, Shan Zhong, Bree Goldstein, Kristen Hopson, Howard A. Burris, Kinjal Mody, Scott K. Pruitt, Alverina Binanti-Berube, Joshua Frederick, Robert S. Meehan, Karen Keating, Justin F. Gainor
Publikováno v:
Journal of Clinical Oncology. 37:2523-2523
2523 Background: T-cell targeting of mutation-derived epitopes (neoantigens) has been demonstrated to drive anti-tumor responses. Immunizing patients against such neoantigens in combination with a checkpoint inhibitor (CPI) may elicit greater anti-tu